MacroGenics, Inc. - Common Stock (MGNX)
1.7800
+0.1400 (8.54%)
NASDAQ · Last Trade: Jun 10th, 6:18 PM EDT
Detailed Quote
Previous Close | 1.640 |
---|---|
Open | 2.010 |
Bid | 1.760 |
Ask | 1.800 |
Day's Range | 1.780 - 2.170 |
52 Week Range | 0.9897 - 5.770 |
Volume | 25,808,478 |
Market Cap | 108.77M |
PE Ratio (TTM) | -2.000 |
EPS (TTM) | -0.9 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 435,482 |
Chart
About MacroGenics, Inc. - Common Stock (MGNX)
Macrogenics is a biotechnology company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and other serious diseases. The company’s research and development efforts aim to harness the power of the immune system to fight tumors, utilizing advanced technologies to engineer molecules that can specifically target and modulate tumor-associated antigens. Macrogenics collaborates with various partners to advance its pipeline of proprietary and partnered programs, including therapies that are currently undergoing clinical trials, with the goal of providing new treatment options for patients with unmet medical needs. Read More
News & Press Releases
Synergy CHC Corp. (NASDAQ: SNYR), a fast-rising force in the consumer health and wellness space, has appointed Damian Marano as Vice President of Beverage in a strategic move aimed at catapulting the company’s FOCUSfactor Energy Drink into global markets. Marano, a seasoned executive with a decorated history at The Coca-Cola Company (NYSE: KO), brings a wealth of expertise that could unlock powerful international distribution opportunities for the brand.
Via AB Newswire · June 10, 2025
Power Metallic Mines Inc. (TSXV: PNPN) (OTCQB: PNPNF) has executed a deal to acquire 100% of 313 mineral claims from Li-FT Power Ltd., expanding its Quebec land position by over 300% to 212.86 km² . The newly acquired claims border the Company’s flagship Nisk Project, surrounding the high-grade Nisk, Lion, and Tiger polymetallic discoveries.
Via AB Newswire · June 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · June 10, 2025

Via Benzinga · November 7, 2024
Via Benzinga · June 10, 2025
By MacroGenics, Inc. · Via GlobeNewswire · June 10, 2025

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL.
By MacroGenics, Inc. · Via GlobeNewswire · June 3, 2025
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.
By MacroGenics, Inc. · Via GlobeNewswire · May 6, 2025
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month:
By MacroGenics, Inc. · Via GlobeNewswire · May 1, 2025
Via Benzinga · March 24, 2025
MGNX earnings call for the period ending December 31, 2024.
Via The Motley Fool · March 20, 2025

ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET
By MacroGenics, Inc. · Via GlobeNewswire · March 6, 2025

ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March:
By MacroGenics, Inc. · Via GlobeNewswire · February 27, 2025

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Macrogenics, Inc. (NASDAQ: MGNX) on behalf of long-term stockholders following a class action complaint that was filed against MGNX on July 26, 2024 with a Class Period from March 7, 2024 to May 9, 2024. Our investigation concerns whether the board of directors of MGNX have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · December 10, 2024

ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
By MacroGenics, Inc. · Via GlobeNewswire · December 2, 2024

MGNX earnings call for the period ending September 30, 2024.
Via The Motley Fool · November 5, 2024

ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:
By MacroGenics, Inc. · Via GlobeNewswire · November 6, 2024

Via Benzinga · November 6, 2024

ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company’s Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process.
By MacroGenics, Inc. · Via GlobeNewswire · October 30, 2024

ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET.
By MacroGenics, Inc. · Via GlobeNewswire · October 29, 2024